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For patients with complex aortic aneurysms that cannot be treated effectively with currently approved endografts, physicians
have made fenestrations in marketed devices and constructed branched grafts by creatively implanting available endograft
components. For themost part, these procedures are being done outside of clinical studies by individual physicians. Although
these novel approaches may be useful in the treatment of individual patients, the current ad hoc use of physician-created
fenestratedandbrancheddevicesmaynot result in theunbiasedcapture andreportingofdata regardingshort-and longer-term
outcomes. As a result, unsubstantiated conclusions regarding the safety and effectiveness of these procedures may be drawn.
Well-designed andexecuted clinical studies are necessary to adequately assess the beneﬁts and risks of these techniques.Because
these interventions involve the use of signiﬁcant risk devices, these studies need to be conducted underUnited States Food and
DrugAdministration-approved InvestigationalDeviceExemptions (IDE) applications. Although this regulatory process adds
complexity to the application of these creative techniques, the IDE regulations assure that patient protection measures are
followed and data are captured to assess safety and effectiveness. This approach creates opportunities to advance the devel-
opment of innovative, beneﬁcial devices and procedures to treat complex aortic aneurysms. (J Vasc Surg 2013;57:823-5.)The ﬁrst fenestrated endograft to treat abdominal obtained from the use of homemade endografts, under
aortic aneurysms with short infrarenal neck lengths was
approved for use in the United States (U.S.) by the U.S.
Food and Drug Administration (FDA) in April 2012.
Even with the approval of this device, which is custom-
designed and imported for each patient, many patients
with complex aortic aneurysms cannot be treated effec-
tively or expeditiously with currently approved endografts.
In response, physicians have developed techniques to make
fenestrations in marketed endografts and to construct
branched grafts by creatively implanting available endograft
components. Most of these procedures are being done
outside of clinical studies on an ad hoc basis by individual
physicians treating individual patients.
The current creative endograft uses are reminiscent of
the “homemade” devices of the 1990s, where off-the-shelf
stents and vascular grafts were sewn together to create
endografts to treat aortic aneurysms. Although there
may have been beneﬁts for individual patients and phy-
sicians from the uses of these early devices, the lack of
rigorous, well-designed clinical studies may have delayed
the transfer of knowledge to efﬁciently advance endograft
technology. Ultimately, systematically captured informationthe United States Food and Drug Administration.
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in implantation techniques and patient selection, followed
by improvements in industry-supported clinical study
protocols and device designs. The long-term data from these
studies have also revealed the limitations of homemade
devices compared with devices manufactured by industry.
As was the case with the homemade endografts, the
current ad hoc use of physician-created fenestrated and
branched devices may not result in the unbiased capture
and reporting of complete and accurate data regarding
device use and short-term and longer-term procedural
outcomes. As a result, unsubstantiated conclusions may
be drawn about the safety and effectiveness of these proce-
dures. Furthermore, appropriate human subject protection
measures, such as the use of an informed consent form that
adequately communicates the unknown risks that may be
associated with these procedures, may be deﬁcient or
absent outside of a formal clinical study.
Recognizing the potential for improved patient treat-
ment given the promising results reported to date, the
practice of physically modifying or constructing branched
endografts is ready to move into a phase of rigorous clinical
investigation. As these investigations advance from single-
center feasibility studies to multicenter studies involving
larger numbers of patients, they will provide invaluable
information to expand the treatment options for patients
with complex aortic aneurysms.
THE INVESTIGATIONAL DEVICE EXEMPTIONS
REGULATIONS AND CLINICAL STUDIES
Clinical studies, deﬁned as any standardized, systematic
collection of safety or effectiveness data, or both, in the823
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(IDE) regulations, which for signiﬁcant-risk studies involve
the submission of an IDE application for approval by the
FDA.1 To explore why IDE applications are needed for
the use of physician-modiﬁed endografts and the creation
of branched devices in vivo, there are three key questions
to consider:
d Is it optimal to justify the use of these devices under
the “practice of medicine,” and therefore miss the
opportunity to collect device performance and clinical
outcome data in a clinical study?
d Are the studies exempt from the IDE regulations?
d Are these signiﬁcant-risk studies?
Practice of medicine. The FDA regulates the
marketing of medical devices, not the practice of medicine.
Section 1006 of the Food, Drug, and Cosmetic Act specif-
ically states that “Nothing in this Act shall be construed to
limit or interfere with the authority of a health care practi-
tioner to prescribe or administer any legally marketed
device to a patient for any condition or disease within
a legitimate health care practitioner-patient relationship.”
One interpretation of the Food, Drug and Cosmetic Act is
that it may be acceptable to create branched endografts
under the practice of medicine. However, making fenes-
trations in a device that has received Premarket Approval
could be interpreted as creating a new investigational
device that would be subject to additional FDA oversight.
The FDA approves a device for marketing for a speciﬁc
use(s).2 Themanufacturer’s product labeling, which contains
the instructions for use (IFU), presents a general description
of the patient population forwhich the device is intended and
the disease or condition that the device will diagnose,
treat, prevent, cure, or mitigate. The labeling also describes
how the device should be used to obtain clinical outcomes
consistent with the data provided to support FDA approval.
Off-label use is a term applied to the use of an approved
device under the practice of medicine outside of the IFU.
The decision to use an approved device off-label or to
use a modiﬁed version of an approved device in treating
a patient is not necessarily inappropriate but is typically sup-
ported by less information than with on-label use. Speciﬁ-
cally, when a physician constructs a branched or fenestrated
endograft, it cannot be assumed that the data collected to
demonstrate the safety and effectiveness of the device when
used on-label or in its unmodiﬁed state are applicable. The
prior nonclinical testing and clinical studies would not have
addressed the off-label or device modiﬁcation aspects of
these innovative uses, such as performing tests that incor-
porate conditions that reﬂect the anatomy and physiology
associated with complex aortic aneurysms or the effects of
combining or modifying devices.
Creative uses of endografts may be associated with
higher rates of major adverse events, particularly in the hands
of inexperienced operators, compared with the anticipated
rates with on-label uses of unmodiﬁed devices. The differ-
ences in expected outcomes may be acceptable given thetypically higher-risk patients being treated but should be
assessed through clinical studies to establish appropriate ex-
pectations by the treating physicians and potential patients.
The information available from presentations and publi-
cations on creative endograft use consists largely of retro-
spective observations and analyses rather than prospective
clinical studies. Although ad hoc device use can provide
insight into the promise and limitations of these techniques,
deﬁnitive data from appropriately designed and conducted
clinical studies are needed to guide informed decisions for
the treatment of complex aortic aneurysms.
Exempted investigations. Some clinical studies, such
as the study of approved devices that are being used on-
label, are exempted from the IDE regulations. A clinical
study of physician-modiﬁed endografts or a study of the
combination of off-the-shelf components to treat aneu-
rysms involving arterial side branches or bifurcations would
be an investigation of a new device or an off-label use, so
would not be exempted.
The testing of a modiﬁcation to a device or of a combi-
nation of two or more legally marketed devices is only
exempted from the IDE regulations if the testing is not
for the purpose of determining safety or effectiveness and
does not put patients at risk. Because there are risks to
patients associated with the creative use of endografts, clin-
ical studies of these uses would not be exempted from the
IDE regulations, even if the data were not intended to
support a marketing application to the FDA.
Signiﬁcant-risk determination. Signiﬁcant-risk de-
vices are those that present the potential for serious risk to
the health, safety, or welfare of a patient. A signiﬁcant-risk
device may be an implant, a life-supporting or life-
sustaining device, or a device of substantial importance in
diagnosing curing, mitigating, or treating disease or in
otherwise preventing impairment of human health. By
deﬁnition, studies of endografts that are subject to the IDE
regulations are signiﬁcant-risk studies.
A clinical study of a signiﬁcant-risk device in the U.S.
requires prior FDA approval, through the submission of an
IDE application, and Institutional Review Board approval
before initiating study subject enrollment.
IDE APPLICATION
The IDE regulations list the information to be in-
cluded in an IDE application. The IDE sponsor needs to
provide sufﬁcient information to justify the proposed study
based on reports of prior investigations of the device, an
appropriate investigational plan, and adequate patient
protection measures. Other required elements of an IDE
application address records and reports, study monitoring,
and manufacturing information.
For physician-sponsored endograft studies, justiﬁcation
for the study would be based primarily on the clinical
expertise of the individual submitting the IDE, historical
information on the development of the techniques proposed,
and a description of the beneﬁts and risks of alternative treat-
ment options. Clinical mitigation strategies (ie, strategies
included in the clinical protocol intended to minimize the
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ical to support the study, particularly when limited nonclinical
testing is available. The rationale for the conduct of the study
should be tailored to the speciﬁc patient population to be
enrolled, for example, patients at high risk for complications
if treated with open surgical repair.
The clinical protocol for a modiﬁed endograft IDE
should contain information similar to that provided under
manufacturer-sponsored IDEs. For example, the protocol
should clearly describe:
d The patients to be enrolled in the study;
d The lesion types and locations to be treated;
d The duration of the study (most endograft IDEs
specify 5-year follow-up for each patient);
d All devices to be used in the study (eg, devices used in
constructing the modiﬁed endograft, covered stents,
bare stents) and how the endograft will be modiﬁed,
if applicable;
d The potential risks that may be associated with the
treatment and how the risks will be minimized; and
d The data to be captured, differentiating between
protocol-required data and optional information.
Incorporation of appropriate monitoring and oversight
will be important and may include the use of a clinical
events committee and a data and safety monitoring board.
The informed consent document for a physician-
sponsored endograft study should contain the required
elements as outlined in 21CFRPart 50 Subpart BeInformed
Consent of Human Subjects. For these studies, prospective
study subjects should be informed of potential beneﬁts
and risks that may be associated with study participation
and that there could be unforeseeable risks due to limitations
in available data and experience with the device. The beneﬁts
and risks associated with the standard of care (eg, open
surgical repair) should also be addressed.
Guidance on the preparation and submission of an IDE
can be found at http://www.fda.gov/MedicalDevices/
DeviceRegulationandGuidance/HowtoMarketYourDevice/
InvestigationalDeviceExemptionIDE/ucm046164.htm.
The preparation of an IDE application and the conduct
of an IDE study can be challenging, requiring a skilled
research staff. Consultation with the device manufacturer
and physicians who have experience with the IDE process
may be helpful. In addition, it is recommended that
a sponsor-investigator interact with the FDA through the
presubmission process when preparing the IDE applica-
tion. This process allows for informal discussion and feed-
back to address key components that need to be included
or revised in the IDE submission.
Information on the presubmission process may be
found in the draft guidance “Medical Devices: The Pre-
Submission Program and Meetings with FDA Staff” at
http://www.fda.gov/MedicalDevices/DeviceRegulation
andGuidance/GuidanceDocuments/ucm310375.htm. Once
ﬁnalized, this guidance will represent the FDA’s current
thinking on this topic.REIMBURSEMENT UNDER IDES
The FDA provides recommendations to the Centers
for Medicare & Medicaid Services (CMS) with respect
to whether an IDE application is for an experimental
(category A) or a nonexperimental/investigational (cate-
gory B) device. A category A device is an innovative device
for which initial questions of safety and effectiveness have
not been resolved and the FDA is unsure whether the device
type can be safe and effective. Category B refers to a device
for which the underlying questions of safety and effective-
ness of that device type have been resolved or it is known
that the device type can be safe and effective.
CMS uses the FDA categorization of a device as a factor
in making Medicare coverage decisions. CMS may consider
for Medicare coverage certain nonexperimental/investiga-
tional (category B) devices being studied under an FDA-
approved IDE application. To date, FDA has categorized
all endografts as nonexperimental/investigational devices
when used in IDE-approved clinical studies. The FDA
makes no recommendations to CMS regarding off-label
use of approved endografts.
Additional information on FDA categorization and
CMS coverage can be found at http://ecfr.gpoaccess.gov/
cgi/t/text/text-idx?c¼ecfr&rgn¼div6&view¼text&node¼
42:2.0.1.2.5.2&idno¼42.
CONCLUSIONS
Modiﬁed endografts and creative implantation proce-
dures have been developed to address unmet clinical needs
in the treatment of complex aortic aneurysms in patients at
a high risk for morbidity and mortality if treated with open
surgery. As clinicians increasingly apply these contemporary
endovascular techniques, appropriate patient protection and
care should be applied. Data from well-designed and
executed clinical studies are needed to optimize patient selec-
tion, treatment, and follow-up. Although the IDE process
adds complexity to the use of novel endovascular therapies,
it should aid in the development of improved technology
and techniques for patients with complex aortic aneurysms.
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